Seta Derderian, Simone Chevalier, Armen Aprikian
Research team at The Institute identifies gene expression signature to help guide treatment decisions for prostate cancer patients
A team led by Simone Chevalier, PhD and Armen Aprikian, MD at the Research Institute of the McGill University Health Centre (The Institute) has developed a promising approach—recently published in the journal Molecular Oncology—that offers a new way to determine how aggressively prostate cancer may behave. By analyzing specific genes in blood RNA, the team has identified distinct expression patterns that could help clinicians predict which patients are at higher risk of progression.
“This work represents a major step toward less invasive, more precise tools for identifying aggressive prostate cancer,” said Prof. Chevalier, a senior scientist in the Cancer Research Program at The Institute. “The ultimate goal is to offer more personalized treatments and target high-risk disease earlier.”